Fig. 4

ALRN-6924 in combination with chemotherapeutic agents inhibits in vivo tumor growth. a Female athymic nu/nu mice bearing MCF-7 and ZR-75-1 xenografts were treated with vehicle, ALRN-6924 5 mg/kg or 10 mg/kg, paclitaxel 10 mg/kg, or the combination of each. All treatments were administered intravenously at the indicated times. Depicted values represent mean ± SEM (n = 5–8). Statistical significance was determined using one-way analysis of variance (ANOVA) analysis of the rate of change in tumor volume. b Using median tumor volume, T/C ratios were obtained. Efficacy defined as < 40% T/C ratio at the end of the studies (28 days for MCF-7 and 26 days for ZR-75-1). c Female athymic nu/nu mice bearing MCF-7 and ZR-75-1 xenografts were treated with vehicle, ALRN-6924 5 mg/kg or 10 mg/kg, eribulin 0.3 mg/kg, or the combination of each. All treatments were administered intravenously at the indicated times. Depicted values represent mean ± SEM (n = 5–8). d Using median tumor volume, T/C ratios were obtained